Connect with Quotient Sciences at the upcoming BIO International Convention 2023 in Boston, MA between June 5-8.

Schedule a meeting

Quotient's Scientific Achievements in 2019

As a company that prides itself on science and innovation, Quotient Sciences has continued to work collaboratively with our customers over the last 12 months to publish research findings from programs of work that we perform. In 2019, Quotient presented 11 podium talks and 13 scientific posters at international conferences, and were involved in four peer reviewed articles published in scientific journals.

We are grateful to our customers who have been willing to have their work published and to all of the scientists involved in the design and delivery of these projects. Sharing the information with the wider pharmaceutical development community will help with our collective goal of accelerating the delivery of new medicines to patients around the world.

Details and links to some of the top papers and posters are below. If there is something of particular interest and you would like further information then please get in touch.

White Papers, Scientific Papers & Articles

WHITE PAPER: Assessing the Financial Impact of Translational Pharmaceutics®
“Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by >12 months and lowers R&D costs by >$100 million per approved new drug, compared to traditional multi-vendor development paradigms.”
Access here

Peer Reviewed Publications

Genentech - Absence of  Pharmacokinetic interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate
Access here

Mitsubishi - Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study
Access here 

DRGT - Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers
Access here
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics
Access here

Scientific Posters

European Paediatric Formulation Initiative (EuPFI)  

"Development of Oral Liquid Products for Neonatal Patients"
Access here

"Development of a Paediatric Oral Suspension of a Novel Drug for the Treatment of Kidney disease"
Access here 

AAPS Pharm Sci 360

"Applications and Benefits of Healthy Volunteer Trials to Accelerate Oncology Drug Development"
Access here 

"Comparison of Two In-Silico Modeling Programs, ADMET Predictor® and Percepta® to Predict Intrinsic Solubility and pKa of Poorly Soluble Drugs"
Access here 

"A Phase I Study Allowing Clinical Screening of Multiple Solubility-Enhancement Formulation Technologies, and an Assessment of Food, PPI and Dose Linearity Assessment with the Selected Formulation of BOS172767, in Healthy Volunteers"
Access here

"Development of a Solubilised Capsule Formulation Using Co-Micronisation and Precipitation Inhibition"
Access here 

"Rapid Transition of a Novel Celecoxib Formulation from a Fit-for-Phase Presentation to a Commercializable Product Using an Innovative Integrated Drug Development and Clinical Testing Platform"
Access here

American Heart Association (AHA)

Huya Biosciences International - "HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation - Phase 1 Study Results"
Access here 

Case Studies

Druggability Technologies (DRGT)

"DRGT is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT-46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US."
Access here

If you have any questions about our services, get in touch.


Share Your Development Challenge with our Scientists
Let's Talk